AC Immune Total Assets 2016-2021 | ACIU

AC Immune total assets from 2016 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
AC Immune Annual Total Assets
(Millions of US $)
2020 $255
2019 $301
2018 $201
2017 $134
2016 $158
2015 $83
AC Immune Quarterly Total Assets
(Millions of US $)
2021-09-30 $222
2021-06-30 $232
2021-03-31 $252
2020-12-31 $255
2020-09-30 $279
2020-06-30 $284
2020-03-31 $298
2019-12-31 $301
2019-09-30 $320
2019-06-30 $296
2019-03-31 $314
2018-12-31 $201
2018-09-30 $212
2018-06-30 $114
2018-03-31 $127
2017-12-31 $134
2017-09-30 $130
2017-06-30 $133
2017-03-31 $144
2016-09-30 $165
2016-03-31 $74
2015-12-31 $83
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.376B $0.016B
AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09